- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07838675
MediPD: An Online Mediterranean Diet Program for People Living With Parkinson's Disease (MediPD)
Feasibility Of An Online Self-management Mediterranean Diet Program To Improve Dietary Behaviour And Quality Of Life For People Living With Parkinson's Disease: The MediPD Pilot Randomised Controlled Trial
The aim of this pilot study is to assess whether an online Mediterranean diet programme called MediPD is acceptable and practical for people living with Parkinson's disease, and whether it can help them make and maintain changes towards a Mediterranean-style diet.
The study will include 120 adults living in the United Kingdom with Parkinson's disease who have access to an internet-enabled device and currently have low adherence to a Mediterranean-style diet. Participants will be randomly assigned to one of two groups. One group will receive access to the MediPD online programme, which includes short educational videos, personalised dietary information, practical resources, goal-setting tools, and online dietetic support. The other group will continue with their usual care and will receive access to MediPD after completing the final study assessment.
Researchers will compare the groups to see whether MediPD improves adherence to a Mediterranean diet after 24 weeks. The study will also examine dietary intake, non-motor symptoms, quality of life, gastrointestinal symptoms, cognitive function, and how acceptable and practical the programme is to use. Assessments will take place at the start of the study, at 12 weeks, and at 24 weeks.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Nicola A Ward, PhD, MSci
- Número de teléfono: +44(0)7823368444
- Correo electrónico: medipd@qub.ac.uk
Copia de seguridad de contactos de estudio
- Nombre: Sinead O'Hagan, MSc
- Número de teléfono: +44(0)7823368444
- Correo electrónico: medipd@qub.ac.uk
Ubicaciones de estudio
-
-
-
Belfast, Reino Unido, BT12 6BA
- Reclutamiento
- Remote assessments from Centre for Public Health, Queens University Belfast
-
Contacto:
- Nicola Ann Ward, PhD, MSci
- Número de teléfono: 07823368444
- Correo electrónico: medipd@qub.ac.uk
-
Contacto:
- Sinead O'Hagan
- Número de teléfono: 07823368444
- Correo electrónico: medipd@qub.ac.uk
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Self-reported idiopathic Parkinson's disease
- Age 18 years or older
- Community-dwelling and resident in the United Kingdom
- Access to an internet-enabled device and an active email address
- Mediterranean Diet Score ≤7/13, indicating low adherence to a Mediterranean diet
- Proficient in English
- Able to provide informed consent
Exclusion Criteria:
- Atypical or secondary parkinsonism
- Living in an institution
- Self-reported body mass index <18.5 kg/m²
- High risk of malnutrition, defined as MUST score ≥2
- Receiving prescribed nutritional support
- Significant cognitive impairment, defined as T-CogS ≤21
- Pregnancy
- Active inflammatory bowel disease
- Dysphagia requiring a pureed diet
- Food allergies that would prevent adherence to a Mediterranean-style diet
- Following a vegan diet that would prevent adherence to the study's Mediterranean-style dietary intervention.
- Current participation in another interventional trial
- Participation in an investigational medicinal product trial within the previous 90 days where this may affect study outcomes or participant burden
- Previous participation in a My Moves Matter dietary programme.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: MediPD Intervention
Participants will receive access to the 12-week MediPD online Mediterranean diet behaviour-change program |
MediPD is a 12-week online Mediterranean diet behaviour-change programme for people with Parkinson's disease. It provides personalised educational videos, practical resources, self-monitoring tools, and moderated dietetic support. Participants are encouraged to complete at least one module per week, aiming to adopt and maintain Mediterranean-style dietary changes over 24 weeks. |
|
Sin intervención: Wait-List Control
Participants will continue to receive their usual care. After completing the final 24-week study assessment, participants in the wait-list control group will be offered access to the MediPD online program for 12 weeks. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Mediterranean Diet Adherence using a Mediterranean Diet Score at 24 Weeks
Periodo de tiempo: Baseline to 24 weeks
|
Adherence to a Mediterranean diet will be assessed using the Mediterranean Diet Score (MDS), derived from a validated 14-item questionnaire. Total scores range from 0 to 14, with higher scores indicating greater adherence to a Mediterranean diet. |
Baseline to 24 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Mediterranean Diet Adherence using a Mediterranean Diet Score at 12 Weeks
Periodo de tiempo: Baseline to 12 weeks
|
Adherence to a Mediterranean diet will be assessed using the Mediterranean Diet Score (MDS), derived from a validated 14-item questionnaire. Total scores range from 0 to 14, with higher scores indicating greater adherence to a Mediterranean diet. |
Baseline to 12 weeks
|
|
Change in self-reported dietary intake using a 24-hour Dietary Recall
Periodo de tiempo: Baseline, 12 weeks and 24 weeks.
|
Dietary intake will be assessed using Intake24, an online 24-hour dietary recall tool. Outcomes will include mean daily intake of energy (kcal/day), foods and macronutrients (g/day and, where appropriate, percentage of energy), and micronutrients (mg or µg/day, as appropriate). Higher values indicate greater intake of food/nutrients. |
Baseline, 12 weeks and 24 weeks.
|
|
Change in Parkinson's Disease Non-Motor Symptoms using the Movement Disorder Society Non-Motor Rating Scale (MDS-NMS)
Periodo de tiempo: Baseline, 12 weeks and 24 weeks.
|
Non-motor symptoms will be assessed using the validated 52-item, rater-administered Movement Disorder Society Non-Motor Rating Scale (MDS-NMS). Total scores range from 0 to 832, with higher scores indicating a greater non-motor symptom burden and a worse outcome. |
Baseline, 12 weeks and 24 weeks.
|
|
Change in reported Gastrointestinal Symptoms using the Gastrointestinal Symptom Rating Scale (GSRS)
Periodo de tiempo: Baseline, 12 weeks and 24 weeks.
|
Gastrointestinal symptoms will be assessed using the 15-item Gastrointestinal Symptom Rating Scale (GSRS). Items are scored from 1 to 7 and summed to provide a total score ranging from 15 to 105. Higher total scores indicate greater gastrointestinal symptom severity and therefore a worse outcome. |
Baseline, 12 weeks and 24 weeks.
|
|
Change in quality of life using the Parkinson's Disease Questionnaire (PDQ-39)
Periodo de tiempo: Baseline, 12 weeks and 24 weeks.
|
Quality of life will be assessed using the 39-item Parkinson's Disease Questionnaire (PDQ-39), which covers eight domains. Each domain score is transformed to a 0-100 scale, and the mean of the eight domain scores provides the PDQ-39 Summary Index. Higher Summary Index scores indicate poorer health-related quality of life and therefore a worse outcome. |
Baseline, 12 weeks and 24 weeks.
|
|
Change in cognitive function using TestMyBrain cognitive test battery
Periodo de tiempo: Baseline, 12 weeks and 24 weeks.
|
Cognitive function will be assessed using the TestMyBrain cognitive test battery, comprising Verbal Paired Associates, Visual Paired Associates, Backward Digit Span, Digit Symbol Matching, and Trail Making A and B. Each test score will be converted to a z-score and oriented so that higher scores consistently indicate better performance. The z-scores will be summed to provide an overall cognitive composite score with higher scores indicating better cognitive function. |
Baseline, 12 weeks and 24 weeks.
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in whole-gut transit time using the Blue Poop Challenge (optional assessment)
Periodo de tiempo: Baseline, 12 weeks and 24 weeks.
|
Consenting participants who opt into this assessment will consume a standardised food-grade blue dye preparation and record the date and time of ingestion and the first appearance of blue colouring in their stool. Whole-gut transit time will be calculated as the elapsed time in hours between ingestion and the first appearance of blue stool. Higher values indicate a longer, slower whole-gut transit time. |
Baseline, 12 weeks and 24 weeks.
|
|
Intervention acceptability using a study-specific semi-structured qualitative interview
Periodo de tiempo: Week 24
|
Intervention acceptability will be explored through a study-specific semi-structured interview with a purposive sample of approximately 10-15 participants from the MediPD intervention group. Interviews will explore satisfaction and acceptability, relevance and usefulness, engagement, feasibility, platform usability, perceived impact, participant burden, barriers and facilitators, and suggestions for improvement. Interviews will be audio-recorded, transcribed verbatim and analysed qualitatively to identify key themes. This assessment does not generate a numerical score and therefore has no minimum or maximum value. |
Week 24
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Claire T McEvoy, PhD, Mphil, RD, Queens University Belfast
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 513675
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .